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The aim of the present study was to examine the relationship between the clinicopathological status, the pre- and postoperative
systemic inflammatory response and survival in patients undergoing potentially curative resection for ductal adenocarcinoma of the
head of the pancreas. Patients (n¼65) who underwent resection of ductal adenocarcinoma of the head of pancreas between 1993
and 2001, and had pre- and postoperative measurements of C-reactive protein, were included in the study. The majority of patients
had stage III disease (International Union Against Cancer Criteria, IUCC), positive circumferential margin involvement (R1), tumour
size greater than 25mm with perineural and lymph node invasion and died within the follow-up period. On multivariate analysis,
tumour size (hazard ratio (HR) 2.10, 95% confidence interval (CI) 1.20–3.68, P¼0.009), vascular invasion (HR 2.58, 95% CI 1.48–
4.50, Po0.001) and postoperative C-reactive protein (HR 2.00, 95% CI 1.14–3.52, P¼0.015) retained independent significance.
Those patients with a postoperative C-reactive protein p10mgl
 1 had a median survival of 21.5 months compared with 8.4 months
in those patients with a C-reactive protein 410mgl
 1 (Po0.001). The results of the present study indicate that, in patients who
have undergone potentially curative resection for ductal adenocarcinoma of the head of pancreas, the presence of a systemic
inflammatory response predicts poor outcome.
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The outlook for patients with ductal adenocarcinoma of the head
of the pancreas remains poor, having the lowest 5-year survival
rate of any cancer (Parker et al, 1996). Surgery remains the only
proven approach for improving survival in these patients.
However, surgery is complicated and is associated with appreciable
morbidity and mortality. As a consequence, potentially curative
surgery is carried out relatively infrequently and usually in a
specialist centre.
The prognosis for patients who undergo potentially curative
resection has been reported to be determined by various
pathologic characteristics of the resected tumour specimen.
Pathologic predictors of survival after surgery include vascular
invasion (Griffanti-Bartoli et al, 1994), perineural invasion
(Hermanek, 1998; Ozaki et al, 1999), histological tumour grade
(Greer and Brennan, 1993), not achieving a clear margin (Yeo et al,
1995) and tumour size (Fortner et al, 1996). Taking all these factors
into account, Fortner and co-workers (1996) reported that, in 52
patients undergoing potentially curative regional pancreatectomy,
tumour size was the strongest predictor of survival independent of
lymph node metastases.
It is increasingly recognised that it is not only the intrinsic
properties of tumour cells which determine tumour spread but
also the host inflammatory response (Balkwill and Mantovani,
2001; Coussens and Werb, 2002). Indeed, the systemic inflamma-
tory response, as evidenced by elevated circulating concentrations
of C-reactive protein, has been shown to be a disease-independent
prognostic factor in a variety of operable tumours (Mahmoud and
Rivera, 2002; McMillan et al, 2003; Ikeda et al, 2003). In particular,
an elevated C-reactive protein, measured either prior to or
following curative surgery, has been shown to predict recurrence
and overall survival, independent of stage, in patients with
colorectal cancer (McMillan et al, 2003).
An elevated C-reactive protein concentration has previously
been shown to have independent prognostic value in patients with
unresectable pancreatic ductal adenocarcinoma (Falconer et al,
1995; Ueno et al, 2000; Engelken et al, 2003). However, to our
knowledge the prognostic value of C-reactive protein has not been
previously examined in patients with operable disease.
The aim of the present study was to examine the relationship
between clinicopathologic status, the systemic inflammatory
response and survival in patients undergoing potentially curative
resection for ductal adenocarcinoma of the head of the pancreas.
PATIENTS AND METHODS
Patients
Patients who on the basis of radiological and pathological staging
underwent resection of ductal adenocarcinoma of the head of
pancreas (between 1st January 1993 and 31st July 2001) had pre-
and postoperative measurements of C-reactive protein, and
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spostoperative measurements of tumour size were included in the
study. Measurement of C-reactive protein was carried out on the
day prior to and approximately 1 month following surgery. All
patients underwent either a classic Whipple’s procedure or a
pylorus preserving resection for removal of ductal adenocarcino-
ma of the head of pancreas. Patients with ampullary, periampullary
and duodenal carcinoma were excluded from study as well as
pancreatic neuroendocrine tumours. Patients presenting either
with cholangitis or other clinical evidence of infection, especially
where the bile culture was positive, were also excluded from study.
All patients were treated in the upper GI surgical unit at Glasgow
Royal Infirmary and survived at least 30 days following surgery.
No patient underwent chemotherapy. The study was approved by
the local ethical committee.
Methods
Tumours were classified by type, along with pathological staging
criteria (size, nodal status, perineural and vascular invasion, and
tumour differentiation). Tumour stage was according to the
International Union Against Cancer Criteria (IUCC). Tumour size
was taken as the largest tumour diameter measured by the
pathologist.
Routine laboratory measurements of albumin and bilirubin were
carried out. C-reactive protein was measured by Fluorescence
Polarisation Immunoassay using an Abbott TDX analyser and
Abbott reagents (Abbott Laboratories, Abbott Park, IL, USA). The
coefficient of variation for this method, over the range of
measurement, was less than 5% as established by routine quality
control procedures. The limit of detection of the assay is a C-
reactive protein concentration of less than 5mgl
 1 with the upper
limit of normal values being p10mgl
 1. Based on previous work
(O’Gorman et al, 2000), a C-reactive protein concentration of
greater than 10mgl
 1 was considered to indicate the presence of a
systemic inflammatory response.
Statistics
Comparisons between groups of patients were carried out using
contingency table analysis (X
2) as appropriate. Survival analysis
was performed using the Cox’s proportional-hazards model.
Deaths up to the end of March 2004 were included in the analysis.
Multivariate survival analysis was performed using a stepwise
backward procedure to derive a final model of the variables that
had a significant independent relationship with survival. To
remove a variable from the model, the corresponding P-value
had to be greater than 0.10. Analysis was performed using SPSS
software (SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics of the patients (n¼65) studied are shown
in Table 1. The majority of patients were under 65 years with
similar numbers of male and female patients. The majority of
patients had stage III disease (IUCC), positive circumferential
margin involvement (R1), tumour size greater than 25mm with
perineural and lymph node invasion. The tumour was well
differentiated in 12%, moderate in 55% and poor in the 32%.
In all, 33 patients (51%) had evidence of a systemic
inflammatory response preoperatively, that is, circulating C-
reactive protein concentration greater than 10mgl
 1. During the
follow-up period, 60 (92%) patients died. The median survival time
was 13.4 months.
On univariate analysis, sex (Po0.05), tumour size (Po0.05),
vascular invasion (Po0.001), preoperative (Po0.001) and post-
operative (Po0.001) C-reactive protein concentrations were
significantly associated with survival (Table 1). On multivariate
analysis of these significant variables, tumour size (hazard ratio
(HR) 2.10, 95% confidence interval (CI) 1.20–3.68, P¼0.009),
vascular invasion (HR 2.58, 95% CI 1.48–4.50, Po0.001) and
postoperative C-reactive protein (HR 2.00, 95% CI 1.14–3.52,
P¼0.015) retained independent significance. The patient group
with no evidence of a postoperative systemic inflammatory
response (C-reactive protein p10mgl
 1) had a median survival
of 21.5 months compared with 8.4 months in the elevated systemic
inflammatory response group (Po0.001).
The relationship between the presence of an elevated preopera-
tive C-reactive protein concentration and tumour characteristics
are shown in Table 2. There was no significant difference in the
stage, presence of positive resection margins, lymph node
metastases or perineural invasion between the inflammatory and
noninflammatory groups. There were a greater number of males
(Po0.05) and tumours were larger (Po0.05), had more vascular
invasion (Po0.05) and had poorer differentiation (Po0.05) in the
elevated C-reactive protein group.
DISCUSSION
Surgical resection remains the only prospect for long-term survival
in patients with ductal adenocarcinoma of the pancreas. Currently,
in patients undergoing surgery, prognostic factors are all based on
the pathological findings from the resected tumour. However, this
means that the assessment of prognosis occurs following a major
operation with significant morbidity and mortality. Therefore, it is
of interest that in the present study an elevated circulating
concentration of C-reactive protein (410mgl
 1), measured
preoperatively, was associated with poor survival and was
associated with pathological criteria indicative of poor outcome.
It has been previously shown that, in patients with primary
operable colorectal cancer, approximately one-third of patients
had an elevated circulating concentration of C-reactive protein
preoperatively and that these patients had a significantly poorer
outcome (McMillan et al, 2003). It was of interest that, in the
present study, the proportion of patients with an elevated
Table 1 Characteristics of patients who underwent potentially curative
resection for ductal adenocarcinoma of the head of the pancreas: univariate
survival analysis
Patients
(n¼65) HR (95% CI) P-value
Age (o65/465 years) 37/28 0.66 (0.39–1.12) 0.127
Sex (f/m) 33/32 1.78 (1.06–2.99) 0.031
Stage (I/II/III) 17/2/46 1.13 (0.83–1.53) 0.449
Resection margin R0/R1 19/46 1.64 (0.92–2.91) 0.094
Tumour size (p25/425mm) 27/38 1.99 (1.14–3.45) 0.015
Lymph node invasion ( /+) 20/45 1.25 (0.71–2.22) 0.444
Perineural invasion ( /+) 6/59 1.01 (0.44–2.37) 0.973
Vascular invasion ( /+) 39/26 2.75 (1.60–4.71) o0.001
Tumour differentiation (well/
moderate/poor)
8/36/21 1.46 (0.97–2.20) 0.072
Albumin (X35/o35gl
 1) 40/25 1.00 (0.59–1.71) 0.987
Bilirubin (p22/422mmoll
 1) 12/53 1.12 (0.56–2.23) 0.750
Biliary stent (no/yes) 32/33 1.06 (0.63–1.76) 0.836
Preoperative
C-reactive protein (p10/
410mgl
 1)
32/33 2.56 (1.51–4.36) o0.001
Postoperative
C-reactive protein (p10/
410mgl
 1)
33/32 2.50 (1.46–4.29) o0.001
CI¼confidence interval; HR¼hazard ratio.
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spreoperative C-reactive protein concentration was approximately
half and that these patients also had a poorer outcome. It may be
that because C-reactive protein concentration is independent of
tumour stage, it might form the basis of a new prognostic score
that reflects not only the tumour response but also that of the host.
Indeed, this approach has recently been used to improve the
prediction of outcome in patients who underwent potentially
curative resection for oesophageal and colorectal cancer (Ikeda
et al, 2003; Canna et al, 2004).
In the present study, an elevated C-reactive protein concentra-
tion, measured either pre- or postoperatively, was associated with
more than a halving of survival. When, in multivariate survival
analysis, an elevated preoperative C-reactive protein was compared
with the postoperative (1 month) value, an elevated postoperative
C-reactive protein better predicted poor survival independent of
pathological criteria. Although from the present results an elevated
postoperative C-reactive concentration is a better predictor of
survival than an elevated preoperative value, in a clinical context,
the measurement of pre- and postoperative C-reactive protein
concentrations are both likely to be of value. The preoperative
measurement, since it may allow planning of adjuvant treatment,
and the postoperative measurement, since it may be useful in the
monitoring of patients who have undergone resection for ductal
adenocarcinoma of the head of the pancreas.
This is a retrospective study and requires verification in larger
prospective cohorts. However, if an elevated C-reactive protein
concentration is shown to predict a poorer prognosis, it may be the
case that patients with potentially resectable ductal adenocarcino-
ma of the head of the pancreas, yet a high inflammatory profile
preoperatively, should not undergo surgery. Alternatively, mod-
ulation of the systemic inflammatory response may be a useful
approach in these patients in the postoperative period.
In summary, the results of the present study indicate that, in
patients who have undergone potentially curative resection for
ductal adenocarcinoma of the head of pancreas, the presence of a
systemic inflammatory response predicts poor outcome.
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